Article outlines topical delivery system for large molecules

An article in the April, 2010 issue of Drug Delivery Technology magazine describes a new topical drug delivery system for delivering large and small molecules in the skin. Written by Praveen Kumar, MPharm, PhD; Angela Perry, MSc; Ravinderjit Batta, MPharm; and M. King, PhD; the article describes the new “Biphasix” topical drug delivery technology and points out how, in the case of treating dermatologic disease states in particular, systemic drug delivery also exposes healthy tissue to the drug and can result in an increased likelihood of toxic side effects.

The authors note that, although technologies, such as iontophoresis, ultrasound, microneedles, and use of permeation enhancers, are being investigated to deliver macromolecules across the skin, there are very few topical biotechnology drug products available. Development of a flexible, easy-to-manufacture, dermal, or transdermal topical drug delivery system would help optimize a drug’s efficacy, safety, and compliance while minimizing toxicity.

Biphasix is a patented drug delivery technology developed by Helix BioPharma Corp.

- read the full story for more

Related Article:
Helix raises $13M for cancer trials

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.